Bayer to acquire Asklepios Bio in foray into gene therapy worth up to $4 billion

FILE PHOTO: A bridge is decorated with the logo of a Bayer AG, a German pharmaceutical and chemical maker in Wuppertal, Germany August 9, 2019. REUTERS/Wolfgang Rattay/File Photo

Bayer to acquire Asklepios Bio in foray into gene therapy worth up to $4 billion

Ethereum Blockchain’s Q1 2024 Success: Unveiling The Factors Behind The $370M Profit Surge

Bitcoin Could Drop To $52,000 If Price Breaks Below This Mark – CryptoQuant

Stanford researchers say large language models favor white-sounding names

FedNow could be that rare tech innovation whose results match the hype

Mortgage rates hit a five-month high

Ask Larry: Does My Husband Need To File In 2021 Retroactively To Get The 2022 Social Security COLA?

Dear Penny: Will My Husband’s Bad Health Choices Drain My Life’s Savings?

Panel Of Experts Reveal When The Cardano Price Will Reach $3

Industry groups sue over Colorado’s crackdown on high-cost lending

FDIC rebukes Sutton Bank, Piermont Bank over fintech partners

Ask Larry: Does My Husband Need To File In 2021 Retroactively To Get The 2022 Social Security COLA?

Ask Larry: Does My Husband Need To File In 2021 Retroactively To Get The 2022 Social Security COLA?

Dear Penny: Will My Husband’s Bad Health Choices Drain My Life’s Savings?

Panel Of Experts Reveal When The Cardano Price Will Reach $3

Industry groups sue over Colorado’s crackdown on high-cost lending

FDIC rebukes Sutton Bank, Piermont Bank over fintech partners

Versace F/W 2024 is for the good girl with a wild soul

Mylo Speech Buddy app to expand language support

Innovative Insurance Brokerage for Creative Freelancers Unveiled

Bosch and R-Biopharm join forces to enhance Vivalytic analysis platform through new medical technology partnership

In latest move, Cadence reorganizes its management structure

“White Paper Uncovers Paradox within Corporate Diversity Initiatives”